EGFR and non-small cell lung carcinoma: Since the identification of specific epidermal growth factor receptor (EGFR) mutations as a critical predictor of therapeutic response of NSCLC patients to gefitinib, an ATP-competitive EGFR tyrosine kinase inhibitor (EGFR-TKI), gefitinib and other recently developed EGFR inhibitors have been the mainstay in the management of NSCLC with activating EGFR mutations [3, 4].